Relx (LON:REL) had its target price raised by Goldman Sachs Group from GBX 2,378 ($31.28) to GBX 2,408 ($31.68) in a research report report published on Monday morning, Stock Target Advisor reports. Goldman Sachs Group currently has a buy rating on the stock.
Several other brokerages have also recently issued reports on REL. Liberum Capital restated a buy rating and issued a GBX 1,750 ($23.02) target price on shares of Relx in a report on Thursday, October 24th. Barclays restated an overweight rating and issued a GBX 2,090 ($27.49) target price on shares of Relx in a report on Friday, October 25th. UBS Group restated a sell rating on shares of Relx in a report on Friday, October 25th. Berenberg Bank raised their target price on shares of Relx from GBX 1,930 ($25.39) to GBX 2,120 ($27.89) and gave the stock a buy rating in a report on Wednesday, January 15th. Finally, HSBC restated a buy rating on shares of Relx in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of GBX 1,933.80 ($25.44).
Shares of Relx stock opened at GBX 2,040 ($26.84) on Monday. The company has a debt-to-equity ratio of 308.02, a quick ratio of 0.40 and a current ratio of 0.45. Relx has a 52-week low of GBX 1,597 ($21.01) and a 52-week high of GBX 2,027 ($26.66). The stock has a market capitalization of $38.74 billion and a price-to-earnings ratio of 26.46. The company’s 50 day moving average price is GBX 1,908.46 and its 200-day moving average price is GBX 1,895.98.
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
See Also: What is Green Investing?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.